Atea Pharmaceuticals, Inc.
AVIR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001593899
In the last 90 days, Atea Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 1 sale; 126 institutions reported holding it in 13F filings for Q3 2026, worth $307.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:17 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 14, 2025 | Feb 28, 2024 | Feb 28, 2023 | Feb 28, 2022 |
| Revenue | – | – | – | – | $351.4M |
| Operating expenses | $180.9M | $192.9M | $164.2M | $130.7M | $213.0M |
| Research and development | $148.0M | $144.1M | $114.2M | $81.9M | $167.2M |
| Selling, general and administrative | $32.9M | $48.8M | $49.9M | $48.7M | $45.8M |
| Operating income | -$180.9M | -$192.9M | -$164.2M | -$130.7M | $138.4M |
| Income tax | -$6.16M | $925.0K | $1.02M | -$3.59M | $17.4M |
| Net income | -$158.3M | -$168.4M | -$136.0M | -$115.9M | $121.2M |
| EPS, basic | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.46 |
| EPS, diluted | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.37 |
| Weighted shares, basic | 81.5M | 84.3M | 83.4M | 83.2M | 82.8M |
| Weighted shares, diluted | 81.5M | 84.3M | 83.4M | 83.2M | 88.2M |
| Margins and growth | |||||
| Operating margin | – | – | – | – | 39.4% |
| Net margin | – | – | – | – | 34.5% |
| Revenue growth, year over year | – | – | – | – | +622.5% |
| Net income growth, year over year | – | – | – | −195.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 14, 2025 | Feb 28, 2024 | Feb 28, 2023 | Feb 28, 2022 |
| Cash and equivalents | $95.7M | $64.7M | $143.8M | $188.5M | $764.4M |
| Total current assets | $311.0M | $462.4M | $590.5M | $660.9M | $772.4M |
| Property, plant and equipment | $457.0K | $873.0K | $1.29M | $1.71M | $23.0K |
| Total assets | $315.2M | $464.7M | $595.0M | $666.7M | $772.9M |
| Accounts payable | $12.9M | $4.46M | $4.25M | $2.55M | $4.53M |
| Total current liabilities | $39.8M | $18.6M | $32.4M | $18.5M | $56.9M |
| Total liabilities | $39.8M | $25.8M | $39.8M | $26.1M | $62.8M |
| Shareholders' equity | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 14, 2025 | Feb 28, 2024 | Feb 28, 2023 | Feb 28, 2022 |
| Operating cash flow | -$132.0M | -$135.5M | -$85.4M | -$121.0M | -$87.0M |
| Capital expenditures | – | – | – | $1.94M | $4.00K |
| Free cash flow | – | – | – | -$122.9M | -$87.0M |
| Depreciation and amortization | $416.0K | $416.0K | $416.0K | $260.0K | $29.0K |
| Stock-based compensation | $20.7M | $51.8M | $49.4M | $46.7M | $39.6M |
| Share buybacks | $25.5M | – | – | – | – |
| Investing cash flow | $188.8M | $56.1M | $40.3M | -$455.4M | -$4.00K |
| Financing cash flow | -$25.7M | $267.0K | $257.0K | $370.0K | $1.47M |
| Net change in cash | $31.0M | -$79.1M | -$44.8M | -$576.0M | -$85.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | – | – | 11.3% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 80.3M | +2.8% | SEC |
| Aug 10, 2026 | 80.2M | +1.1% | SEC |
| May 11, 2026 | 80.0M | −6.5% | SEC |
| Mar 4, 2026 | 79.7M | −6.8% | SEC |
| Nov 10, 2025 | 78.1M | −7.5% | SEC |
| Aug 4, 2025 | 79.4M | −6.0% | SEC |
| May 9, 2025 | 85.6M | +1.6% | SEC |
| Mar 4, 2025 | 85.5M | +1.6% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.